Adjusted EBT
The Adjusted EBITDA Total for continuing operations amounted to € 1,986.7 million in the first nine months of 2024 and was thus 1.4% higher than the prior-year value of € 1,958.4 million in the first nine months of 2023.
In the 2024 reporting period, the non-recurring items eliminated in the Adjusted EBT came to € 220.2 million (9M 2023: € 157.9 million). The following table gives a detailed list of the non-recurring items:
Non-recurring Items
Non-recurring Items | ||||||||
in € million | 9M 2023 | 9M 2024 | Change in % | 12M 2023 | ||||
Transactions* | 102.0 | 29.3 | -71.3 | 70.0 | ||||
Personnel matters | 36.7 | 164.3 | >100 | 35.1 | ||||
Business model optimization | 13.6 | 21.3 | 56.6 | 34.9 | ||||
Research & development | 5.1 | 4.6 | -9.8 | 6.8 | ||||
Refinancing and equity measures | 0.5 | 0.7 | 40.0 | 1.1 | ||||
Total non-recurring items | 157.9 | 220.2 | 39.5 | 147.9 | ||||
- *Including one-time expenses in connection with acquisitions, such as HR measures relating to the integration process and other follow-up costs.
The increase in HR-related non-recurring items is due to the reassessment of the probability of claims being asserted in connection with legal disputes with a social insurance provider.